Starting Buprenorphine in Residential Treatment: The COWS Score, Fentanyl, and What to Ask Admissions

Families calling about residential treatment for opioid use often ask one question first: “Will they keep him on his medication?” The second question, usually asked later and with more worry, is “If she isn’t on anything yet, can they start it there?” Those are two different admissions questions, and programs answer them differently. This guide explains how buprenorphine is started in a residential setting, what the COWS score measures, and exactly what to confirm with admissions before the intake date.

Starting Buprenorphine Is a Timed Medical Step, Not a Prescription Handed Over

Buprenorphine is one of the medications for opioid use disorder recognized by the National Institute on Drug Abuse (NIDA) and addressed in the American Society of Addiction Medicine (ASAM) National Practice Guideline. Starting it, a process clinicians call induction or initiation, is timed. Because buprenorphine binds tightly to opioid receptors but activates them only partially, taking the first dose while full-agonist opioids such as fentanyl, heroin or oxycodone are still occupying those receptors can push a person abruptly into withdrawal. That is called precipitated withdrawal, and avoiding it is the main reason the first dose is scheduled around a measured withdrawal score rather than a clock.

In practice, the first day in a residential program that starts buprenorphine on-site looks like this: the person arrives, completes the medical intake, and is then observed. Nursing staff reassess withdrawal on a schedule. When the score shows enough withdrawal, the prescriber approves a first dose, and the person is reassessed again afterward. Many people describe that first wait as the hardest part of week one: restless legs, yawning, gooseflesh, a running nose and the feeling that time has stopped. Knowing in advance that the wait is deliberate makes it easier to get through.

What the COWS Score Measures

The Clinical Opiate Withdrawal Scale (COWS) is an 11-item clinician-rated checklist scored from 0 to 48, used to measure opioid withdrawal before and after a buprenorphine dose. A nurse rates observable signs including resting pulse, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. The commonly used bands are 5 to 12 for mild withdrawal, 13 to 24 for moderate, 25 to 36 for moderately severe, and above 36 for severe. Each program’s prescriber sets the score at which a first dose is given, so families should ask for that program’s threshold rather than assume one.

The score matters because it turns “I feel terrible” into something a prescriber can act on safely. It also gives the person in treatment something concrete: a number that is moving, which tells them the plan is working.

Why Fentanyl Changed the First Few Days

Clinicians across the field have adjusted induction practices as fentanyl has replaced heroin and pills in much of the street supply. The reasons are worth understanding before admission:

• Fat-tissue storage: Fentanyl is highly fat-soluble and can be released from body tissue for longer than its short half-life suggests, so withdrawal may build more slowly and unevenly.
• Unknown supply: Street pills sold as oxycodone or other opioids often contain fentanyl, so the last-use history a person gives may not reflect what they actually took.
• Precipitated withdrawal risk: Dosing too early is more likely when fentanyl is still active, which is why some prescribers wait for a higher score or use alternative starting approaches.
• Mixed substances: Fentanyl in the supply is frequently combined with other sedatives, which changes how a medical team monitors the first 24 to 72 hours.

Some prescribers now use lower-dose or “micro-induction” starts for selected patients, where small buprenorphine doses overlap with the existing opioid for several days. Whether a program offers that option, and for whom, is a clinical decision made by its prescriber. It is a fair question to ask.

Safety: Alcohol and Benzodiazepines Change the Plan

Opioid withdrawal is extremely uncomfortable but is rarely life-threatening on its own in otherwise healthy adults. Alcohol and benzodiazepine withdrawal are different: both can cause seizures and other dangerous complications, and both require medical supervision. Anyone who uses alcohol daily or takes benzodiazepines such as alprazolam, clonazepam or lorazepam, prescribed or not, should never stop abruptly, and must tell admissions about that use before the intake date. Combining opioids with alcohol or benzodiazepines also raises overdose risk. If you are worried someone has overdosed, call 911 immediately. For confidential treatment referral, the SAMHSA National Helpline is available 24 hours a day at 1-800-662-4357.

The Operational Truth: Not Every Residential Program Starts Buprenorphine On-Site

From placement work across our network, this is the gap families most often miss. Some residential programs will continue buprenorphine for someone who arrives already on a stable dose but do not start it on-site. Others start it routinely. Some accept people on methadone only if a dosing arrangement with an opioid treatment program can be made in advance, since methadone for opioid use disorder is dispensed through federally certified clinics. A program’s website rarely spells this out. The answer usually lives with the medical director, and the only reliable way to get it is to ask directly.

A related change helps. Since the Consolidated Appropriations Act of 2023 removed the federal “X-waiver” requirement, any clinician with a standard DEA registration that includes Schedule III can prescribe buprenorphine for opioid use disorder. That widened who can prescribe, but it did not make every residential program set up to manage an on-site start. Staffing, nursing coverage overnight and the program’s medical model still decide that.

Five Questions to Ask Admissions Before the Intake Date

Write these down and ask them on the next admissions call. Ask for the answers in writing if you can.

1. Do you start buprenorphine on-site, or only continue it? If only continue, ask where the person would be inducted first and how the handoff works.
2. Who is the prescriber, and how often are they available? Ask whether a prescriber can approve a dose overnight or on a weekend.
3. What COWS score do you use before the first dose, and how often is it rechecked? A clear answer here is a good sign of an organized medical process.
4. What is your plan for fentanyl exposure? Ask whether lower-dose starts are available and how precipitated withdrawal is managed if it happens.
5. How does the prescription continue after discharge? Ask who writes the first outpatient prescription and whether a follow-up appointment is booked before the person leaves. A gap of even a few days after discharge is a known risk period.

If you have not yet confirmed coverage, run a benefits check at the same time; our insurance verification page explains what that check tells you. You can also call our team at (877) 328-1968 and we will help you put these questions to the programs you are considering.

What Families Usually Notice in the First Week

Families often expect the person they love to sound better on the first phone call. Sometimes they do. More often, the first call comes on day two or three and sounds flat or irritable, which is consistent with a body adjusting to a new medication and a structured schedule. By the end of the first week, many people report sleeping more normally and thinking less about using. That is the stabilization a residential treatment setting is designed to protect, so that therapy, family sessions and discharge planning can do their work.

Medication is not a shortcut around treatment, and it is not a substitute for one. It is one part of a plan, and it works best when the plan around it is clear before admission day.

Talk With Someone Who Knows the Programs

Bodhi Addiction Treatment & Wellness helps individuals and families in Northern California and beyond find residential programs that match their medical needs, including whether buprenorphine can be started or continued on-site. Learn more about our founder and clinical reviewer, Jonathan Beazley, CADC-CAS, M-RAS, CCMI-i, or call (877) 328-1968 to talk through your options today.

This article is for educational purposes only and is not medical advice. Medication decisions, including whether and when to start buprenorphine, must be made by a licensed prescriber who has evaluated the individual. Do not stop alcohol, benzodiazepines or any prescribed medication without medical supervision. If you or someone you know is in immediate danger, call 911. For a mental health or substance use crisis, call or text 988.